Gilead Sciences (NASDAQ:GILD) Upgraded at DZ Bank
DZ Bank upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The brokerage currently has $108.00 price objective on the biopharmaceutical company’s stock. Several other equities analysts have also issued reports on GILD. Piper […]
DZ Bank upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The brokerage currently has $108.00 price objective on the biopharmaceutical company’s stock. Several other equities analysts have also issued reports on GILD. Piper […]
